Picture of Novartis AG logo

NVS Novartis AG Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapNeutral

Annual cashflow statement for Novartis AG, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line8,07124,0186,9558,57211,939
Depreciation
Amortisation
Non-Cash Items3,842-11,7144,4042,4035,517
Discontinued Operations
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-4,727-3,346-4,304-4,794-4,436
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities13,65015,07114,23614,45817,619
Capital Expenditures-2,585-2,971-2,671-2,753-3,814
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-10,5977,1794,1398,349-3,699
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities-13,1824,2081,4685,596-7,513
Financing Cash Flow Items-19994553,478-207
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities-2,208-16,264-20,562-14,278-11,742
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-1,4542,749-4,8905,876-1,934